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Abstract
Background: To develop content validity of a comprehensive patient-reported outcome (PRO) measure following
current best scientific methodology to standardize assessment of influenza (flu) symptoms in clinical research.
Methods: Stage I (Concept Elicitation): 1:1 telephone interviews with influenza-positive adults (≥18 years) in the US
and Mexico within 7 days of diagnosis. Participants described symptom type, character, severity, and duration.
Content analysis identified themes and developed the draft Flu-PRO instrument. Stage II (Cognitive Interviewing):
The Flu-PRO was administered to a unique set of influenza-positive adults within 14 days of diagnosis; telephone
interviews addressed completeness, respondent interpretation of items and ease of use.
Results: Samples: Stage I: N = 46 adults (16 US, 30 Mexico); mean (SD) age: 38 (19), 39 (14) years; % female:
56 %, 73 %; race: 69 % White, 97 % Mestizo. Stage II: N = 34 adults (12 US, 22 Mexico); age: 37 (14), 39 (11)
years; % female: 50 %, 50 %; race: 58 % White, 100 % Mestizo. Symptoms: Symptoms identified by >50 %:
coughing, weak or tired, throat symptoms, congestion, headache, weakness, sweating, chills, general
discomfort, runny nose, chest (trouble breathing), difficulty sleeping, and body aches or pains. No new
content was uncovered during Stage II; participants easily understood the instrument.
Conclusions: Results show the 37-item Flu-PRO is a content valid measure of influenza symptoms in adults
with a confirmed diagnosis of influenza. Research is underway to evaluate the suitability of the instrument for
children and adolescents. This work can form the basis for future quantitative tests of reliability, validity, and
responsiveness to evaluate the measurement properties of Flu-PRO for use in clinical trials and epidemiology
studies.
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Background
Influenza is a contagious, viral illness characterized by
mild to severe symptoms that may lead to death [1]. In
the United States (US), influenza and its complications
result in approximately 111 million lost work days, $7
billion/year in sick days and lost productivity, 30 million
clinic visits, 226,000 hospitalizations and 3,000 to 49,000
deaths annually [2–4]. Worldwide influenza and its com-
plications result in an estimated 3–5 million cases of se-
vere illness and approximately 250,000–500,000 deaths
every year [5]. In patients who survive, much of the dis-
ability from influenza is due to bothersome symptoms
that impair their ability to function.
Currently, there is no standardized, validated patient-
reported outcome (PRO) measure for influenza and
influenza-like symptoms developed according to
accepted scientific standards [6–8]. A comprehensive,
precise measure would facilitate understanding of the
natural history and epidemiology of influenza as well as
quantify its severity and recovery patterns of disease and
its variability within and across populations. Combined
with other baseline variables, quantification of symptoms
would help define and standardize severity of illness
measures for influenza. For prevention trials, a validated
measure could be used to standardize and document the
presence and severity of symptoms in patients who de-
velop the disease. For treatment trials, a precise, disease-
specific PRO symptom measure would be more sensitive
to treatment effects, particularly time-to-event (symp-
tom improvement) analyses. A standardized tool across
studies would facilitate meta-analyses and comparisons
of interventions.
The purpose of this study was to begin to develop a
PRO instrument to standardize the assessment of
influenza (Flu) symptoms, the Flu-PRO, by evaluating
content validity using methods recommended by the US
Food and Drug Administration (FDA) [6] and good
research practices [7, 8].
Methods
Study design and setting
A two-stage qualitative instrument development meth-
odology was followed, involving adults (≥18 years) with
laboratory-confirmed influenza recruited through clin-
ical sites in the US and Mexico. Stage I involved con-
cept elicitation interviews with the target population to
gather information regarding patient experience of in-
fluenza symptoms, including type, magnitude, expres-
sion, pattern of onset, and recovery. From this, a draft
item pool and conceptual framework were developed
for the new Flu-PRO instrument, including its content
and structure (item phrasing, length, response options,
recall, instructions). Stage II consisted of cognitive in-
terviews to assess completeness, comprehension, and
interpretability of the draft Flu-PRO instrument from the
respondent’s perspective. Qualitative, semi-structured tele-
phone interviews were utilized in both stages. Patients
with laboratory-confirmed influenza were recruited from
military treatment facilities or associated clinics in the US
(six clinics in San Diego, CA; Portsmouth, VA; Tacoma,
WA; San Antonio, TX; Jacksonville, NC; and Bethesda,
MD), and the Mexico Emerging Infectious Diseases
Clinical Research Network (LaRed) in Mexico, which
consisted of three hospitals: Instituto Nacional de Ciencias
Médicas y Nutrición Salvador Zubirán (Nutricion),
Instituto Nacional de Enfermedades Respiratorias (INER),
and Hospital General Dr. Manuel Gea. The protocol for
both stages was approved by Institutional Review Boards
at the Uniformed Services University and at both the US
and Mexico sites.
Stage I: concept elicitation interviews
The purpose of the concept elicitation interviews was to
elicit participants’ descriptions of their influenza symp-
toms to inform the content and structure of the new
measure. The following inclusion criteria were used to
recruit potential participants from US sites: 1) aged
18 years or older; 2) eligible for care in Department of
Defense facilities (DEERS eligible); 3) symptoms consist-
ent with influenza-like illness (ILI): a) Fever with body
temperature ≥100.4 °F [38 °C] AND respiratory symp-
toms OR b) Subjective fever AND respiratory Symp-
toms; 4) able to speak in English; and 5) able to provide
written informed consent. Respiratory symptoms were
defined as: cough, or sputum production, or shortness of
breath, or chest pain, and/or sore throat.
Exclusion criteria were: 1) self-report of concurrent
asthma or chronic obstructive pulmonary disease (COPD)
exacerbation; 2) concurrent pneumonia symptoms with
clinical evidence confirming bacterial pneumonia, i.e.,
pleural effusion or empyema, consolidated single lobar
pneumonia documented by radiological testing with
otherwise normal lung fields, or bacteremia with a patho-
gen known to cause pneumonia; 3) any other relevant
condition that would interfere with participants’ ability to
participate in a one-on-one telephone interview; and 4)
complicated pregnancy.
For the Mexico participants, the following inclusion
criteria were used to recruit participants: 1) aged 18 years
or older; 2) enrolled in an existing influenza natural
history study at the Mexico sites that included swab for
influenza testing; 3) Spanish speaking; and 4) able to
provide written informed consent. Exclusion criteria
were: 1) any relevant condition that would interfere with
their ability to participate in a one-to-one telephone
interview; and 2) declined consent to having their inter-
view audio-record interview.
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All participants with ILI who met these criteria were
enrolled and interviewed for this study; however, only
those who were later shown to have a laboratory-
confirmed influenza diagnosis were included in the ana-
lysis. This ensured the concepts elicited in developing
the new questionnaire were from participants known to
have confirmed influenza, rather than another ILI. Both
inpatients and outpatients were eligible for inclusion. In
both the US and Mexico, all participants’ influenza diag-
nostic procedure was performed as part of existing
studies’ protocols and not specifically for the purpose of
the Flu-PRO development study. These tests included
rapid antigen testing (RAT) and real time reverse-
transcription polymerase chain reaction (RT-qPCR) for
influenza. Available results classified patients as influ-
enza positive or negative, but did not further classify
patients by type of influenza, as the medical literature
poses the symptoms of influenza are similar across types
of influenza and types of ILI.
Participants provided written informed consent at
the recruitment site and were scheduled for a tele-
phone interview with the study research team. A
semi-structured interview guide was used to facilitate
the interviews, with open-ended questions asking par-
ticipants to describe their symptoms and characterize
their nature, severity, onset, duration, variability, and
indictors of recovery. Information on the importance
or impact of symptoms was gathered to understand
the relative importance of symptoms from a content
validity perspective.
All interviews were conducted by trained researchers.
US interviews were conducted in English by research
staff from Evidera (Bethesda, MD) and interviews in
Mexico were conducted in Spanish by staff from the
LaRed network using the translated interview guide. At
the end of the interview, participants were asked socio-
demographic and clinical/health-related questions, with
data used to characterize the sample. Interviews were
transcribed verbatim, with the data cleaned and de-
identified for analyses. Mexico interviews were translated
by an external translation company (FACIT - Functional
Assessment of Chronic Illness Therapy group; Chicago,
IL) for analyses in English.
A coding dictionary was developed by examining ini-
tial transcript data to identify key themes and constructs
participants expressed during the interviews. The
software program ATLAS.ti (version 5.0) was used to
facilitate the systematic analysis of data. All transcripts
were then coded thematically and reviewed by a second
analyst, with any discrepancies resolved through discus-
sion with the primary or senior analyst. Symptoms that
emerged from the interviews were tracked on a grid to
monitor saturation, defined as the point at which add-
itional sampling offered no new information [9]. US data
from adult participants were collected and analyzed first
and to the point of saturation. Data collected from
Mexico were analyzed using the same coding dictionary,
assessing symptoms reported and noting any differences
with US results.
Development of the Flu-PRO instrument
The multi-disciplinary Flu-PRO development team used
results of the concept elicitation interviews to draft an
English version of the Flu-PRO instrument, including
items, instructions, recall period, and response options.
This ensured the instrument was grounded in the words
and phrases that patients with influenza commonly use
to describe the symptoms they experienced. A translata-
bility assessment was performed by an expert in PRO
instrument translation and ePRO formatting to ensure
translatability of words and phrases, and suitability of
conversion to ePRO format.
An item definition dictionary and translation instruc-
tions were then developed and the draft Flu-PRO instru-
ment was translated into Spanish using methods to
ensure conceptual equivalence [10]. The steps involved
in using this method were: 1) two forward translations
by native speakers of Spanish; 2) one reconciled version
of the two forwards by a third native speaker of Spanish;
3) one back translation of the reconciled version into
English by an English speaker fluent in Spanish; 4)
comparison of source text and back-translated text to
identify possible discrepancies by FACIT staff; 5) review
of the translations and FACIT comments by the bilingual
language coordinator (LC) for Spanish; 6) finalization of
the translations by the LC for Spanish; 7) quality review
and resolution of any outstanding harmonization issues
by FACIT; and 8) formatting by FACIT staff and proof-
reading of the final questionnaire by two professional
translators who are native speakers of Spanish. Prior to
its use in the cognitive interviews, investigators from
Mexico reviewed the translated version to assure
consistency with the words and phrases participants
from Mexico used during the elicitation phase.
Stage II: cognitive interviews
The purpose of the cognitive interviews was to assess
subject comprehension and interpretability of the Flu-
PRO, its ease of use, and completeness. The exclusion
criteria and recruitment processes were the same as
those used in the concept elicitation interviews outlined
above. However, only participants with laboratory-
confirmed influenza were enrolled within two weeks of
diagnosis. A semi-structured interview guide was used
to facilitate the cognitive interviews; questions assessed
content coverage and participants’ understanding and
interpretation of the Flu-PRO questionnaire (instruc-
tions, items, response options, recall period) with an
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open-ended question asking if there were any additional
symptoms the person had experienced that were not
covered in the questionnaire. As before, interviews were
audio-recorded and transcribed verbatim. Sociodemo-
graphic and clinical/health-related questions were asked
at the end of the interview with data used to characterize
the sample. Mexico interviews were conducted in Span-
ish, transcribed, and translated into English for analyses.
Item-by-item analyses were performed to assess clarity
and consistency in interpretation across subjects, and to
determine the need for adjustments or editorial changes
before the instrument was finalized for quantitative
evaluation.
Results
Stage I: concept elicitation interviews
Sociodemographic and clinical characteristics
The sociodemographic and clinical characteristics of the
concept elicitation study sample are presented in Table 1.
The average age of US participants was 38.4 years and
39.0 years in Mexico. Female participants composed
56.3 % and 73.3 % of the US and Mexico groups, re-
spectively. In the US, 68.8 % of participants identified
themselves as White. In Mexico, the most common
racial identification was Mestizo (96.7 %). The time from
first symptoms to interview was approximately 5.4 days
in the US sample.
Themes (influenza symptoms)
Twenty symptom categories were identified from the US
sample (Table 2). Symptom saturation was met, meaning
no new themes or ideas were expressed by US partici-
pants during the last round of interviews. All themes
were identified in both the US and Mexico participant
interviews, except for two additional symptoms unique
to the Mexico participants; “feeling warm/hot (not cold)”
and “sun/light sensitivity”(Table 2). Although a number
of participants mentioned signs (fever) or diagnoses
(dehydration, ear infection), these specific concepts were
not considered candidates for the Flu-PRO symptom
measure since they did not directly reflect patients’
symptomatic experience, and symptoms of fever
(warmth, chills, etc.) are already captured in other items.
Symptom themes were evaluated relative to influenza
symptoms reported in the literature and on two public
health websites (Table 3). The elicited concepts were
similar between inpatients and outpatients or between
patients diagnosed by RT-qPCR or RAT.
Flu-PRO development
Symptoms were reviewed and discussed by the multi-
disciplinary Flu-PRO team. Candidate items, response
options, and structure (e.g., instructions and format)
were developed, together with a conceptual framework
for the instrument, using body systems as the
organizational structure (see Fig. 1). For ease of use, a 5-
point severity scale was selected, from “not at all” to
“very much” for 32 items; 5-point frequency scales were
used for vomiting and diarrhea (0 times to 4 or more
times) and sneezing, coughing, and productive cough
(never to always). Symptoms that were conceptually
similar but worded differently by different participants
were included in the item pool in order to subject the
alternatives to qualitative and quantitative testing. For
example, “scratchy or itchy throat”, “sore or painful
throat”, “swollen throat”, and “difficulty swallowing”
were all used to describe symptoms associated with a
sore or inflamed throat. Rather than select one, all were
included as candidate items for empirical testing. The
instrument was formatted for ease of completion by
paper-pen in a clinic or home setting, with minimal
wording, check boxes, and gridlines. The format was also
intended for ease of conversion to electronic format,
including web-based or tablet, with no change in wording
and minimal adjustments in appearance [11].
Stage II: cognitive interviews
Sociodemographic and clinical characteristics
The sociodemographic and clinical characteristics of the
study sample are presented in Table 1.
Understanding, saturation, and endorsement
Participants in both the US and Mexico samples had a
good understanding of the instructions, recall period,
response options, and the majority of the symptom
items on the questionnaire. Participants considered the
content and items to be relevant to their recent and/or
previous influenza experiences. No new symptoms arose
during the interviews, indicating symptom saturation
had been reached during Stage 1.
As expected, participants identified symptom items they
considered overlapping and/or highly related: “sore
throat”, “swollen throat”, and “difficulty swallowing” (n = 5
US; n = 4 Mexico); ‘felt lightheaded” and “felt dizzy” (n = 5
US; n = 2 Mexico); and “head congestion”, “sinus pres-
sure”, and “headache” (n = 4 US; n = 11 Mexico). Add-
itionally, two participants from the US identified “sore and
painful eyes” and “eyes sensitive to light” as overlapping.
Participants from Mexico also identified the following
overlapping/highly related symptoms: “sinus pressure”,
“nasal congestion”, and “runny or drippy nose” (n = 10);
“trouble breathing” and “nasal congestion” (n = 6); “chest
tightness”, “pain with breathing or coughing”, and “mus-
cular/general pain” (n = 5); and “body aches or pains” with
“other” symptoms (n = 4). Because these comments were
expected and raised by a relatively small number of people
in this qualitative study, all of the items were retained for
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testing in a large, quantitative study, and flagged for
additional consideration.
Stage III psychometric testing is currently underway
and as part of this process, patients were timed in filling
out the questionnaire. The total time to fill out the
questions was approximately five minutes, showing low
respondent burden and ease of use for clinical research
studies.
Figure 2 shows the most frequently reported influenza
symptoms by country, organized by body system. The
symptoms participants rated as most severe, by country,
are shown in Fig. 3.
Discussion
The purpose of this study was to develop a new PRO
influenza symptom measure (Flu-PRO) for adults
using accepted methods to assure content validity. A
comprehensive, precise, and standardized method for
evaluating symptoms of influenza is important for
natural history studies, tracking severity and burden
of illness and clinical trials for prevention and treat-
ment of influenza. Development of valid content in a
standardized outcome assessment assures capturing a
comprehensive assessment of patients’ symptom expe-
riences with influenza, allowing both an accurate as-
sessment of the burden of symptoms and comparison
within and between studies.
Concept elicitation interviews amongst patients with
confirmed influenza generated a range of symptoms
and symptom descriptions that were consistent with
symptoms described in the literature (Table 3). The re-
sults of this study showed a more comprehensive array
of symptoms than those assessed in previous PRO in-
struments, including both systemic and gastrointestinal
symptoms in addition to upper and lower respiratory
symptoms. Results from Stage I were used in the
Table 1 Stage I and II: sample characteristics by country










Mean (SD) 38.4 (18.8) 39.0 (13.5) 37.0 (14.1) 38.6 (11.4)
Range 19.0–84.0 22.0–67.0 22.0–65.0 23.0–55.0
Gender (N, %)
Female 9 (56.3) 22 (73.3) 6 (50.0) 11 (50.0)
Ethnicity (N, %)
Not Hispanic or Latino 15 (93.8) 0 (0.0) 11 (91.7) 0 (0.0)




3 (18.8) 0 (0.0) 0 (0.0) 0 (0.0)
Asian 2 (12.5) 0 (0.0) 1 (8.3) 0 (0.0)
Black or African
American
2 (12.5) 0 (0.0) 4 (33.3) 0 (0.0)
White 11 (68.8) 1 (3.3) 7 (58.3) 0 (0.0)
Mestizo 1 (6.3) 29 (96.7) 0 (0.0) 22 (100.0)
Other 2 (12.5) 0 (0.0) 0 (0.0) 0 (0.0)
Educational status
adults (N, %)
Less than high school 0 (0.0) 4 (13.3) 0 (0.0) 0 (0.0)
High school graduate
or equivalent





15 (93.8) 18 (60.0) 11 (91.7) 15 (68.2)
Other 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6)




5.4 (2.3) <7 12.1 (4.3) 10.8 (9.9)
First notice symptoms
to clinic visit
1.8 (1.2) <7 2.7 (2.9) 4.0 (4.5)
Clinic visit to interview
date
3.6 (2.0) <7 9.4 (3.7) 6.8 (7.4)
Medications for influenzaa
(N, % Yes)
None 1 (6.3) 0 (0.0) 2 (16.7) 0 (0.0)
Oseltamivir (Tamiflu) 8 (50.0) 15 (50.0) 6 (50.0) 9 (40.9)
OTC symptom relief 13 (81.2) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 9 (75.0) 19 (86.4)
Health conditions (N, %)
None 9 (56.3) 18 (60.0) 4 (33.3) 13 (59.1)
Asthma or other lung
condition
0 (0.0) 0 (0.0) 3 (25.0) 7 (31.8)
Depression 0 (0.0) 0 (0.0) 2 (16.7) 0 (0.0)
Diabetes 1 (6.3) 5 (16.7) 1 (8.3) 0 (0.0)
Table 1 Stage I and II: sample characteristics by country
(Continued)
Heart attack/angina 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0)
Hypertension 1 (6.3) 0 (0.0) 4 (33.3) 2 (9.1)
Kidney disease 0 (0.0) 0 (0.0) 2 (16.7) 0 (0.0)
Lung disease 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0)
Osteoporosis 1 (6.3) 0 (0.0) 1 (8.3) 0 (0.0)
Raised cholesterol 1 (6.3) 0 (0.0) 2 (16.7) 0 (0.0)
Stomach ulcer 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0)
Tuberculosis 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0)
Other health
conditions
6 (37.5) 0 (0.0) 4 (33.3) 3 (13.6)
Cardiovascular disorder 0 (0.0) 4 (13) 0 (0.0) 0 (0.0)
Abbreviations: OTC over the counter; aParticipants could choose more than
one response
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development of candidate items, instructions, recall
period, response options, and format for the Flu-PRO
instrument. Care was taken to ensure that the items
were phrased using words used by the interview
participants. Cognitive interviews suggested excellent
symptom coverage and completeness. Participants
completed the Flu-PRO quickly and easily, and they
understood the instrument content as intended. Clus-
ters of symptoms considered similar, highly related, or
redundant will be examined quantitatively during the
item reduction phase of Stage III. The concepts
elicited applied to both inpatients and outpatients
with influenza, so the Flu-PRO could be useful in
inpatients who can self-report. The elicited concepts
did not differ by method of diagnosis (RAT or RT-
qPCR), so the Flu-PRO should be generalizable
regardless of the diagnostic test used.
Outcomes in clinical trials and epidemiologic studies
of influenza have included clinician global assessments
of signs and symptoms, symptom scales developed
based on investigator opinion, and previously developed
influenza symptom instruments. Two previous PRO
symptom instruments specific to influenza have been
described in the literature: the Influenza Symptom
Severity Scale (ISS; [12]) and the symptom domain of
the Influenza Intensity and Impact Questionnaire
(FluiiQ™; [13]). The Influenza Wellbeing Scale (IIWS;
[12]) has also been presented; however, this is a well-being
scale rather than a symptom diary. The ISS is an 11-item
measure that includes nasal congestion, sore throat,
cough, aches and pains, fatigue, headache, feeling feverish,
Table 2 Concept elicitation: influenza symptoms by country
Symptom Totals
US (N = 16) Mexico (N = 30)
N % N %
Cough 16 100 % 29 97 %
Throat symptoms 15 94 % 23 77 %
Headache 15 94 % 27 90 %
Weakness 14 88 % 26 87 %
Tired/lack of energy 13 82 % 21 70 %
Body pain 13 81 % 24 80 %
Sweating 13 81 % 18 60 %
General discomfort 12 75 % 24 80 %
Chills 11 69 % 23 77 %
Runny nose 11 69 % 18 60 %
Congestion 11 69 % 16 53 %
Gastrointestinal (nausea, vomit, diarrhea) 9 56 % 19 63 %
Chest (trouble breathing) 8 50 % 14 47 %
Sleep disruption 8 50 % 18 60 %
Loss of appetite 7 44 % 12 40 %
Sinus pressure 5 31 % 2 7 %
Hot and cold 4 25 % 13 43 %
Eye irritation 3 19 % 9 30 %
Dizzy/lightheaded 2 13 % 4 13 %
Sneezing 1 6 % 8 27 %
Feeling warm/hot 0 0 % 11 37 %
Sun/light sensitivity 0 0 % 6 20 %
Table 3 Influenza symptoms in the literature and professional
websites
System symptom Number of published papers
(n= 32) or websitesa (n= 3)
with this symptom (N= 35)
Upper respiratory
Nasal congestion (e.g., obstruction,
stuffiness)
14 (40.0 %)
Rhinorrhea (runny nose) 13 (37.1 %)
Sneezing 4 (11.4 %)
Sore throat 26 (74.3 %)
Hoarseness 3 (8.6 %)
Ear ache and/or pressure 4 (11.4 %)
Conjunctivitis 1 (2.9 %)
Sinus pain 1 (2.9 %)
Coryza 2 (5.7 %)
Nasal symptoms 2 (5.7 %)
Lower respiratory
Cough 29 (82.9 %)
Dyspnea/difficulty breathing 4 (11.4 %)
Chest congestion 1 (2.9 %)
Chest discomfort 2 (5.7 %)
Systemic
Headache 22 (62.9 %)
Muscle/joint aches and pains 25 (71.4 %)
Fatigue (weakness, tiredness, low energy) 16 (45.7 %)
Loss of or poor appetite 6 (17.1 %)
Vomiting 7 (20 %)
Nausea 3 (8.6 %)
Diarrhea 4 (11.4 %)
Digestive symptoms 2 (5.7 %)
Feverishness, chills, rigors, sweats 16 (45.7 %)
Dizziness 2 (5.7 %)
Malaise 3 (8.6 %)
Fatigue/weakness/tiredness/low energy 15 (42.9 %)
Signs
Fever 32 (91.4 %)
aWebsites: World Health Organization (WHO); National Institute for Allergy and
Infectious Disease (NIAID); Centers for Disease Control (CDC)
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nausea, loss of appetite, disturbed sleep, and poor concen-
tration, each rated on a 4-point severity scale ranging from
0 (absent) to 3 (severe) and summed to yield a total score.
Content was based on information from a medical text-
book of influenza rather than patients from the target
population, and results of quantitative testing suggest
noteworthy error in the total score (Cronbach’s alpha of
0.66, N = 52) [12].
The FluiiQ™ is a multi-dimensional instrument de-
signed to improve on the ISS and IIWS, with domains
measuring influenza symptoms (10 items), impact on
daily activities (6 items), impact on emotions (4 items),
and impact on others (5 items). Development of the
FluiiQ™ included expert physician consultation (n = 7),
focus group with college students with confirmed influ-
enza (n = 6), and a concept mapping exercise with
patients with a recent history of confirmed influenza in
Australia (n = 16). The latter task asked participants to
respond to a seeding statement asking how their recent
flu episode had affected them and their lives. Cognitive
interviews were performed with patients participating in
focus groups. Content of the symptom domain of the
FluiiQ™ includes headache, feeling feverish, body aches,
fatigue, neck pain, interrupted sleep, loss of appetite,
• Runny or dripping nose 
• Congested or stuffy nose 
• Sneezing 
 
• Scratchy or itchy throat 
• Sore or painful throat 
• Swollen throat 
• Difficulty swallowing 
 
• Teary or watery eyes 
• Sore or painful eyes 
• Eyes sensitive to light 
 
• Trouble breathing 
• Chest congestion 
• Chest tightness 
• Dry or hacking cough 
• Wet or loose cough 
• Coughing 
• Coughed up mucus or phlegm 
 
• Headache 
• Head congestion 
• Sinus pressure 
• Felt dizzy 
• Felt lightheaded 
 
• Lack of appetite (did not feel like 
eating) 
• Felt nauseous (feeling like you 
wanted to throw-up) 
• Stomach ache 
• Vomit (frequency) 
• Diarrhea (frequency) 
 
• Sleeping more than usual 
• Difficulty staying asleep 
• Difficulty falling asleep 
 
• Body aches or pains 
• Weak or tired 
• Chills or shivering 
• Felt cold 
• Felt hot 
• Sweating 





Flu Symptoms:  














Fig. 1 Flu-PRO draft conceptual framework
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Fig. 2 Cognitive interviews: Most frequently reported influenza symptoms, by system and country. *Symptoms also reported by participants with
influenza in Mexico. **Symptoms also reported by participants with influenza in the US
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Fig. 3 Cognitive interviews: FLU-PRO symptom Items rated as most severe, by country
Powers et al. BMC Infectious Diseases  (2016) 16:1 Page 9 of 11
cough, sore throat, and nasal congestion. Quantitative
testing (N = 311) showed two symptom factors, systemic
(7 items) and respiratory (3 items), with internal
consistency reliability (Cronbach’s alpha) levels of 0.85
and 0.48, respectively. These two scales and an overall
symptom score (alpha = −0.82) were responsive to
change over time and correlated with the impact
domains of the FluiiQ™ [13]. Limitations of the symptom
domain of the FluiiQ™ include the restricted number
and type of symptoms assessed (e.g., absence of gastro-
intestinal symptoms, which have been noted as a part of
the symptoms in newly emerging types of influenza),
low reliability of the respiratory domain, and the embed-
ded positioning within the larger FluiiQ™. We have also
noted in this and previous work that the term “feverish-
ness” relates to a multi-dimensional concept; therefore,
the symptoms encompassed by the single word “fever-
ishness” may not be clearly understood by patients. Our
previous work showed that “fever” can relate to up to 16
different types of symptoms [14]. In the Flu-PRO, the
various symptoms associated with fever are evaluated
separately (warmth, chills, etc.) to increase understand-
ing of respondents and allow for greater clarity on indi-
vidual symptoms. Fever as a sign can be measured by
body temperature measurements rather than PROs. Fi-
nally, the ISS and FluiiQ™ do not note the evaluation of
inpatients with influenza, while inpatients were included
in the development and evaluation of the Flu-PRO.
A focused, comprehensive PRO assessment of influ-
enza symptoms for both inpatients and outpatients is
needed in order to compare and contrast the type
and severity of influenza symptoms across strains and
sub-populations, and provide greater precision in clin-
ical trials evaluating symptom severity and recovery
as an efficacy endpoint. Flu-PRO is a symptom scale
developed using current best scientific practices for
development of PROs. The development process for
the Flu-PRO assures that the symptoms captured are
comprehensive and important to patients, and that
the wording used is clearly understood by patients
who would use the instrument. The concepts in-
cluded in the Flu-PRO were endorsed by both inpa-
tients and outpatients with laboratory-confirmed
influenza by RAT and/or RT-qPCR.
While we enrolled patients who were ill enough to
seek medical care, we did enroll patients with range
of symptoms form mild to severe. Patients with less
severe symptoms may have less intensity of symptoms
but the concepts elicited are similar to those in more
severe disease.
The next phase of the development process will be
quantitative evaluation of the measure in English and
Spanish-speaking adults in the US and Mexico, which is
ongoing. Analyses will include item and factor analysis
with item reduction and tests of score reliability, val-
idity, and responsiveness. Research is also underway
to examine the suitability of the Flu-PRO instrument
for children and adolescents.
Conclusion
This paper describes the qualitative methods used to
optimize the content validity of the new Flu-PRO. Further
research is required to test the quantitative properties of
the items and scores generated by this new measure.
When the latter is secured, the Flu-PRO will be available
for use as a standardized method for evaluating symptoms
of influenza in natural history studies and clinical trials.
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